Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Nasdaq

CrowdStrike Holdings Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on CrowdStrike Holdings (NASDAQ:CRWD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Roivant' Dermavant Showcases New Long-Term Durability, Tolerability Data For Plaque Psoriasis Candidate

Roivant Sciences Ltd's (NASDAQ: ROIV) subsidiary Dermavant Sciences announced results from Phase 3 PSOARING 3 long-term extension study of tapinarof cream 1% for plaque psoriasis in adults.

Benzinga

Jazz Pharma Building New State-Of-The-Art Facility For Cannabis-Based Research And Production

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals have begun construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne, UK, with an investment of over $100 million.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Britain Police Arrests Suspects Behind Okta, Microsoft Hacks

Britain Police arrested seven people following a series of hacks by the Lapsus$ hacking group, Reuters reports.

Benzinga

Check Out What Whales Are Doing With MSTR

Someone with a lot of money to spend has taken a bearish stance on MicroStrategy (NASDAQ:MSTR). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Looking At Apple's Recent Whale Trades

Someone with a lot of money to spend has taken a bullish stance on Apple (NASDAQ:AAPL). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

NVIDIA Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on NVIDIA. Looking at options history for NVIDIA (NASDAQ:NVDA) we detected 41 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

ThermoGenesis Holdings's Earnings: A Preview

ThermoGenesis Holdings (NASDAQ:THMO) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that ThermoGenesis Holdings will report an earnings per share (EPS) of $-0.06.

Benzinga

Eyenovia's Earnings Outlook

Eyenovia (NASDAQ:EYEN) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Eyenovia will report an earnings per share (EPS) of $-0.22.

Benzinga

Earnings Preview For Reshape Lifesciences

Reshape Lifesciences (NASDAQ:RSLS) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Reshape Lifesciences will report an earnings per share (EPS) of $-0.17.

Benzinga

Trxade Group Earnings Preview

Trxade Group (NASDAQ:MEDS) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Trxade Group will report an earnings per share (EPS) of $-0.15.

Benzinga

Earnings Outlook For Hallador Energy

Hallador Energy (NASDAQ:HNRG) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Hallador Energy will report an earnings per share (EPS) of $-0.02.

Benzinga

Earnings Outlook For Venus Concept

Venus Concept (NASDAQ:VERO) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Venus Concept will report an earnings per share (EPS) of $-0.10.

Benzinga

Mid-Morning Market Update: Markets Mixed; US Pending Home Sales Index Drop 4.1%

U.S. stocks traded opened on a mixed note this morning, with the Dow Jones gaining around 80 points on Friday.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Analyzing Lam Research Corporation's Short Interest

Lam Research Corporation's (NASDAQ:LRCX) short percent of float has risen 9.77% since its last report. The company recently reported that it has 2.03 million shares sold short, which is 1.46% of all regular shares that are available for trading.

Benzinga

Analyst Ratings For Ollie's Bargain Outlet

Ollie's Bargain Outlet (NASDAQ:OLLI) has observed the following analyst ratings within the last quarter:

Benzinga

Dave & Buster's Enter's Earnings: A Preview

Dave & Buster's Enter (NASDAQ:PLAY) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Dave & Buster's Enter will report an earnings per share (EPS) of $0.61.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 25, 2022

Upgrades For Aris Water Solutions Inc (NYSE:ARIS), Capital One upgraded the previous rating of Equal-Weight to Overweight. The stock has a 52-week-high of $19.16 and a 52-week-low of $10.06. At the end of the last trading period, Aris Water Solutions closed at $18.55.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Preview: Brainstorm Cell's Earnings

Brainstorm Cell (NASDAQ:BCLI) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Brainstorm Cell will report an earnings per share (EPS) of $-0.20.

Benzinga

Looking Into Yumanity Therapeutics's Return On Capital Employed

Benzinga Pro data, Yumanity Therapeutics (NASDAQ:YMTX) reported Q4 sales of $762.00 thousand. Earnings fell to a loss of $10.41 million, resulting in a 4.57% decrease from last quarter.

Benzinga

ADMA Biologics's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, ADMA Biologics's (NASDAQ:ADMA) reported sales totaled $26.38 million. Despite a 6.0% increase in earnings, the company posted a loss of $16.65 million.

Benzinga

Looking Into PhaseBio Pharmaceuticals's Return On Capital Employed

Benzinga Pro data, PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported Q4 sales of $158.00 thousand. Earnings fell to a loss of $43.11 million, resulting in a 35.04% decrease from last quarter.

Benzinga

Looking Into TFF Pharmaceuticals's Return On Capital Employed

Benzinga Pro data, TFF Pharmaceuticals (NASDAQ:TFFP) reported Q4 sales of $12.00 thousand. Earnings fell to a loss of $10.05 million, resulting in a 15.8% decrease from last quarter.

Benzinga

Recap: DXP Enterprises Q4 Earnings

DXP Enterprises (NASDAQ:DXPE) reported its Q4 earnings results on Friday, March 25, 2022 at 09:20 AM. Here's what investors need to know about the announcement.

Benzinga

Looking Into Sigma Labs's Return On Capital Employed

According to Benzinga Pro data, during Q4, Sigma Labs (NASDAQ:SGLB) posted sales of $349.24 thousand. Earnings were up 3.76%, but Sigma Labs still reported an overall loss of $2.40 million.

1 … 767 768 769 770

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Places

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.